The Fenway Health team joins CoVPN 3502 COVID Prevention TrialBOSTON—Fenway Health has announced that the Boston-based community health center has been activated as a late-stage clinical trial site for the CoVPN 3502 monoclonal antibody study to prevent COVID-19 disease among household members of recently diagnosed people.This study will examine the efficacy of REGN-COV2, Regeneron Pharmaceuticals’ investigational double-antibody combination for the prevention of COVID-19.
This Phase 3 trial will evaluate REGN-COV2’s ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient, such as the patient’s housemate or partner.